TABLE 6.
Total costs and mean cost per patient-year*
| Resource | Budesonide- formoterol (n=1058), $ | Salmeterol- fluticasone (n=1065), $ |
|---|---|---|
| Hospitalization | ||
| Intensive care | 16,138.00 | 8,966.00 |
| General care | 48,450.00 | 88,179.00 |
| Emergency room visits | 5,655.00 | 8,121.00 |
| Physician visits | ||
| GP/FP | 5,501.00 | 6,245.00 |
| Specialist (respirologist) | 4,043.00 | 5,670.00 |
| Other health care visits | 963.00 | 1,925.00 |
| Physician home visits | 1,345.00 | 1,549.00 |
| Other health care home visits | 0.00 | 629.00 |
| Subtotal nondrug costs | 82,095.00 | 121,283.00 |
| Study drug costs | ||
| Budesonide-formoterol | 1,218,452.00 | 0.00 |
| Salmeterol-fluticasone | 0.00 | 1,320,040.00 |
| Salbutamol MDI (generic) | 217.00 | 66,846.00 |
| Concomitant drug costs | ||
| Prednisone | 1,056.00 | 1,588.00 |
| Subtotal drug costs | $1,219,724.00 | 1,388,474.00 |
| Total health system costs | $1,301,820.00 | 1,509,757.00 |
| Mean cost/patient-year | $1,315.00 | 1,541.00 |
| Days of missed work | ||
| Patient | 204,952.00 | 259,686.00 |
| Caregiver | 15,876.00 | 47,295.00 |
| Total societal costs | 1,522,647.00 | 1,816,738.00 |
| Mean cost/patient-year | 1,538.00 | 1,854.00 |
*
Data excluded patients who did not complete the trial or had missing data. FP Family physician; GP General practitioner; MDI Metered dose inhaler